retatrutide glp-1 gip glucagon agonist is a triple-agonist (GLP-1 + + glucagon) and recent clinical trials are showing remarkable outcomes in obesity treatment. 🔬 Latest data highlights: • ~25–30% average body-weight reduction in long-term trials Real results. Real support. Quantity:16oz Flavour: Unflavoured

retatrutide glp-1 gip glucagon agonist is a triple-agonist (GLP-1 + + glucagon) and recent clinical trials are showing remarkable outcomes in obesity treatment. 🔬 Latest data highlights: • ~25–30% average body-weight reduction in long-term trials Real results. Real support. Quantity:16oz Flavour: Unflavoured

Real results. Real support. Real transformation ✨ This glow-up didn't happen overnight, it happened with consistency, guidance, and a customized plan. ✔️ 148 lbs down with 1.5 years on our weight loss

It has no Health Canada or FDA approval and exists, for now, only as an investigational compound and a research chemical

Flavour: Unflavoured

Quantity:16oz

According to Vox, drugs like Ozempic and Wegovy are often excluded from insurance coverage especially if they are used for weight loss